Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Surgical Oncology, Fujian Provincial Hospital, Fuzhou, China.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2186684. doi: 10.1080/21645515.2023.2186684. Epub 2023 Apr 5.
Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for GC to clarify the research status and identify potential new research directions. VOS viewer and CiteSpace visualization software were used to demonstrate collaborations and correlations. A total of 1141 English publications from 2012 to 2022 were included. The number of publications increased year by year. The publications were mainly from China ( = 579, 50.70%), followed by the United States. Fudan University published the most publications ( = 48, 4.21%). and ranked first in cited and co-cited journals, respectively. Kim Kyoung-Mee published the most publications on immunotherapy for GC ( = 14). The clustering of timeline view and co-cited references show the hotspot transformation on immunotherapy for GC. Initially, the hot topic was "cytokine-induced killer cells" and "myeloid-derived suppressor cells." In recent years, the focus has turned to "targeted therapy." "CAR-T" has become the hottest topic, and GC has entered precision therapy phase. Screening patients who can benefit from immunotherapy is key to improving prognosis. The combination of immunotherapy with other treatment options, such as chemotherapy and targeted therapy, is currently the focus of research. Chimeric antigen receptor T cell will be further studied in the future.
胃癌(GC)是最常见的恶性肿瘤之一。免疫疗法已成为 GC 不可或缺的一部分。本研究对 GC 的免疫疗法进行了文献计量分析,以阐明研究现状并确定潜在的新研究方向。VOS viewer 和 CiteSpace 可视化软件用于展示合作和相关性。共纳入 2012 年至 2022 年的 1141 篇英文出版物。出版物数量逐年增加。出版物主要来自中国( = 579,50.70%),其次是美国。复旦大学发表的出版物最多( = 48,4.21%)。 和 分别在被引和共被引期刊中排名第一。Kim Kyoung-Mee 在 GC 的免疫治疗方面发表的出版物最多( = 14)。时间线视图和共被引参考文献的聚类显示了 GC 免疫治疗的热点转变。最初,热门话题是“细胞因子诱导的杀伤细胞”和“髓系来源的抑制细胞”。近年来,重点转向“靶向治疗”。“CAR-T”已成为最热门的话题,GC 已进入精准治疗阶段。筛选能从免疫治疗中获益的患者是改善预后的关键。免疫疗法与化疗和靶向治疗等其他治疗选择的结合是目前研究的重点。嵌合抗原受体 T 细胞将在未来得到进一步研究。